JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology

Core Insights - JCR presented non-clinical data demonstrating the efficiency of its proprietary JUST-AAV platform in delivering AAV gene therapy [1] Company Summary - The JUST-AAV platform is highlighted for its capability to achieve efficient delivery of AAV gene therapy [1]